Lexeo Therapeutics (LXEO) Other financing activities (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Other financing activities data on file, last reported at $9000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $9000.0; the trailing twelve-month figure through Mar 2026 stood at -$94.5 million (changed N/A YoY), and the FY2025 full-year result was $59000.0, down 87.98% from the prior year.
• Other financing activities slipped to $9000.0 in Q1 2026, from $25000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $88.8 million in Q1 2024 to a low of -$94.5 million in Q4 2024.
• A 5-year average of $67111.1 and a median of $25000.0 in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities soared 739508.33% in 2024 and soared 100.03% in 2025, its largest moves.
• Tracing LXEO's Other financing activities over 5 years: stood at $28000.0 in 2022, then advanced by 7.14% to $30000.0 in 2023, then plunged by 315126.67% to -$94.5 million in 2024, then soared by 100.03% to $25000.0 in 2025, then slumped by 64.0% to $9000.0 in 2026.
• Business Quant data shows LXEO's Other financing activities at $9000.0 in Q1 2026, $25000.0 in Q4 2025, and -$94.5 million in Q4 2024.